


PHARMACEUTICAL 2022

GALECTIN THERAPEUTICS INC Rank 359 of 475







PHARMACEUTICAL 2022

GALECTIN THERAPEUTICS INC Rank 359 of 475

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 38% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -299%, being 22% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	41,820
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,033
Liabilities, Non-Current	0
Other Assets	7.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	30,178
Other Net Income	-348
Property and Equipment	0
Research and Development	23,818
Revenues	0
Selling, General and Administrative Expense	6,361

Output Variable	Value in 1000 USD
Assets	41,827
Liabilities	39,211
Expenses	30,179
Stockholders Equity	2,616
Net Income	-30,527
Comprehensive Net Income	-30,527
Economic Capital Ratio	-299%

